Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug122 | AVIGAN 200 MG Film Tablets Wiki | 0.41 |
drug1116 | EIDD-2801 Wiki | 0.33 |
drug2497 | Placebo (PBO) Wiki | 0.29 |
Name (Synonyms) | Correlation | |
---|---|---|
drug2496 | Placebo (PB0) Wiki | 0.29 |
drug1540 | Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets Wiki | 0.29 |
drug120 | AVICOD 200 MG Film Tablet Wiki | 0.29 |
drug1114 | EG-HPCP-03a Wiki | 0.29 |
drug2910 | SARS-CoV-2 Specific T Cells Wiki | 0.29 |
drug1115 | EG-HPCP-03a Placebo Wiki | 0.29 |
drug263 | Anxiety Reduction Training Wiki | 0.29 |
drug1851 | Lopinavir/ Ritonavir Oral Tablet Wiki | 0.29 |
drug1775 | Kundalini Yoga and Anxiety Reduction Training Wiki | 0.29 |
drug3556 | Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures Wiki | 0.29 |
drug1269 | FAVIRA 200 MG Film Tablet Wiki | 0.29 |
drug1987 | Meditation and Anxiety Reduction Training Wiki | 0.29 |
drug1539 | Hydroxychloroquine Sulfate Tablets Wiki | 0.20 |
drug2032 | Methylprednisolone Wiki | 0.15 |
drug401 | Baricitinib Wiki | 0.10 |
drug3430 | Tocilizumab Wiki | 0.09 |
drug2827 | Remdesivir Wiki | 0.05 |
drug3191 | Standard of Care Wiki | 0.04 |
drug2490 | Placebo Wiki | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
D030341 | Nidovirales Infections NIH | 0.20 |
D003333 | Coronaviridae Infections NIH | 0.13 |
D003428 | Cross Infection NIH | 0.13 |
Name (Synonyms) | Correlation | |
---|---|---|
D012327 | RNA Virus Infections NIH | 0.10 |
D012141 | Respiratory Tract Infections NIH | 0.10 |
D011024 | Pneumonia, Viral NIH | 0.10 |
D003141 | Communicable Diseases NIH | 0.08 |
D007239 | Infection NIH | 0.07 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D014777 | Virus Diseases NIH | 0.06 |
D012140 | Respiratory Tract Diseases NIH | 0.06 |
D000860 | Hypoxia NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.05 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.05 |
D055371 | Acute Lung Injury NIH | 0.05 |
D011014 | Pneumonia NIH | 0.05 |
D001008 | Anxiety Disorders NIH | 0.05 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0011947 | Respiratory tract infection HPO | 0.10 |
HP:0012418 | Hypoxemia HPO | 0.05 |
HP:0002090 | Pneumonia HPO | 0.05 |
Navigate: Correlations HPO
There are 12 clinical trials
Background: There are no proven therapies specific for Covid-19. The full spectrum of Covid-19 ranges from asymptomatic disease to mild respiratory tract illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The efficacy of corticosteroids in viral ARDS remains controversial. Methods: This is an internationally (Spain, Canada, China, USA) designed multicenter, randomized, controlled, open-label clinical trial testing dexamethasone in mechanically ventilated adult patients with established moderate-to-severe ARDS caused by confirmed Covid-19 infection, admitted in a network of Spanish ICUs. Eligible patients will be randomly assigned to receive either dexamethasone plus standard intensive care, or standard intensive care alone. Patients in the dexamethasone group will receive an intravenous dose of 20 mg once daily from day 1 to day 5, followed by 10 mg once daily from day 6 to day 10. The primary outcome is 60-day mortality. The secondary outcome is the number of ventilator-free days at 28 days. All analyses will be done according to the intention-to-treat principle.
Description: All-cause mortality at 60 days after enrollment
Measure: 60-day mortality Time: 60 daysDescription: Number of ventilator-free days (VFDs) at Day 28 (defined as days being alive and free from mechanical ventilation at day 28 after enrollment, For patients ventilated 28 days or longer and for subjects who die, VFD is 0.
Measure: Ventilator-free days Time: 28 daysThe Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized infectious disease of the respiratory tract. Most cases are mild or asymptomatic. However, around 5% of all patients develop Acute Respiratory Distress Syndrome (ARDS), which is the leading mortality cause in these patients. Corticosteroids have been tested in deferent scenarios of ARDS, including viral pneumonia, and the early use of dexamethasone is safe and appears to reduce the duration of mechanical ventilation in ARDS patients. Nevertheless, no large, randomized, controlled trial was performed evaluating the role of corticosteroids in patients with ARDS due SARS-CoV2 virus. Therefore, the present study will evaluate the effectiveness of dexamethasone compared to control (no corticosteroids) in patients with moderate and severe ARDS due to SARS-CoV2 virus.
Description: Ventilator-free days, defined as alive and free from mechanical ventilation, at 28 days after randomization.
Measure: Ventilator-free days Time: 28 days after randomizationDescription: Evaluation of the clinical status of patients on the 15th day after randomization defined by the 6-point Ordinal Scale, this scale ranges from 1 (Not hospitalized) to 6 (Death) with higher scores meaning worse outcomes.
Measure: Evaluation of the clinical status Time: 15 days after randomizationDescription: All-cause mortality rates at 28 days after randomization.
Measure: All-cause mortality Time: 28 days after randomizationDescription: Number of days of mechanical ventilation from randomization to day 28.
Measure: Mechanical ventilation duration Time: 28 days after randomizationDescription: Sequential Organ Failure Assessment (SOFA) Score 48 hours, 72 hours and 7 days after randomization
Measure: Sequential Organ Failure Assessment (SOFA) Score Time: Score at 48 hours, 72 hours and 7 days after randomizationDescription: Intensive Care Unit free days, defined as alive and discharged from the intensive care unit, at 28 days after randomization.
Measure: Intensive Care Unit free days Time: 28 days after randomizationThe investigators reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.
The overall objective of the study is to determine the therapeutic effect and tolerance of Tocilizumab combined with Dexamethasone in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19). Tocilizumab (TCZ) is an anti-human IL-6 receptor monoclonal antibody that inhibits signal transduction by binding sIL-6R and mIL-6R. The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering Dexamethasone alone or Dexamethasone +Tocilizumab administration to patients enrolled in the CORIMUNO-19 cohort. Tocilizumab will be administered to consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or critical pneumonia requiring mechanical ventilation. Patients who will chose not to receive Tocilizumab will receive standard of cares. Outcomes of Tocilizumab-treated patients will be compared with outcomes of standard of care (including Dexamethasone) treated patients
Description: Survival without needs of ventilator utilization (including non invasive ventilation and high flow) at day 14. Thus, events considered are needing ventilator utilization (including Non Invasive Ventilation, NIV or high flow), or death.
Measure: Survival without needs of ventilator utilization at day 14 Time: day 14Description: WHO progression scale: Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2>=150 OR SpO2/FIO2>=200: 7 Mechanical ventilation, (pO2/FIO2<150 OR SpO2/FIO2<200) OR vasopressors (norepinephrine >0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2<150 AND vasopressors (norepinephrine >0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10
Measure: WHO progression scale at day 7 and 14 Time: day 7 and day 14Description: Overall survival
Measure: Overall survival at 14, 28, 60 and 90 days Time: 14, 28, 60 and 90 daysDescription: Cumulative incidence of discharge alive
Measure: Cumulative incidence of discharge alive at 14 and 28 days Time: 14 and 28 daysDescription: Survival without needs of mechanical ventilation at day 1. New DNR order (if given after the inclusion of the patient) will be considered as an event at the date of the DNR.
Measure: Survival without needs of mechanical ventilation at day 1 Time: day 1Description: Cumulative incidence of oxygen supply independency
Measure: Cumulative incidence of oxygen supply independency at 14 and 28 days Time: 14 and 28 daysA randomized clinical trial designed and intended to evaluate the efficacy of Dexamethasone and Methylprednisolone as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by coronavirus disease 19 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.
Description: The number of participants with "Clinical improvement" determined by the improvement of individual presenting symptoms of the COVID19; changes in radiological and laboratory values.Patient admitted in general bed requiring High Dependency Unit (HDU), and an HDU patient requiring Ventilator or Intensive care support.
Measure: Clinical improvement Time: Following randomization 30 days.Description: Oxygen saturation in the peripheral blood determined by pulse oximetry.
Measure: Changes in Oxygen level Time: Following randomization 30 days.We aim to assess the benefits and harms of higher (12 mg) vs lower doses (6 mg) of dexamethasone on patient-centered outcomes in patients with COVID-19 and severe hypoxia.
Description: Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 28
Measure: Days alive without life support at day 28 Time: Day 28 after randomisationDescription: Serious adverse reactions defined as new episodes of septic shock, invasive fungal infection, clinically important gastrointestinal bleeding or anaphylactic reaction
Measure: Number of participants with one or more serious adverse reactions Time: Day 28 after randomisationDescription: Death from all causes
Measure: All-cause mortality at day 28 Time: Day 28 after randomisationDescription: Death from all causes
Measure: All-cause mortality at day 90 Time: Day 90 after randomisationDescription: Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 90
Measure: Days alive without life support at day 90 Time: Day 90 after randomisationDescription: Number of days alive and out of hospital not limited to the index admission
Measure: Days alive and out of hospital at day 90 Time: Day 90 after randomisationDescription: Death from all causes
Measure: All-cause mortality at day 180 Time: Day 180 after randomisationDescription: Assessed by EQ-5D-5L
Measure: Health-related quality of life at day 180 Time: Day 180 after randomisationDescription: Assessed by EQ-VAS
Measure: Health-related quality of life at day 180 Time: Day 180 after randomisationrandomized controlled trial comparing survival benefit of Tocilizumab therapy with dexamethasone in patients with severe COVID 19
Description: survival 14 days from admission date
Measure: Proportion of participants with Overall Survival at 14 days Time: 14 daysDescription: Change in Fio2/Pao2
Measure: Fio2/Pao2 Time: 2 daysBackground: There are no proven therapies specific for pulmonary dysfunction in patients with acute hypoxemic respiratory failure (AHRF) caused by infections (including Covid-19). The full spectrum of AHRF ranges from mild respiratory tract illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The efficacy of corticosteroids in AHRF and ARDS caused by infections remains controversial. Methods: This is a multicenter, randomized, controlled, open-label clinical trial testing dexamethasone in mechanically ventilated adult patients with established AHRF (including ARDS) caused by confirmed pulmonary or systemic infections, admitted in a network of Spanish ICUs. Eligible patients will be randomly assigned to receive dexamethasone: either 6 mg/d x 10 days or 20 mg/d x 5 days followed by 10 mg/d x 5 days. The primary outcome is 60-day mortality. The secondary outcome is the number of ventilator-free days at 28 days. All analyses will be done according to the intention-to-treat principle.
Description: All-cause mortality at 60 days after randomization
Measure: 60-day mortality Time: 60 daysDescription: Number of ventilator-free days (VFDs) at Day 28 (defined as days being alive and free from mechanical ventilation at day 28 after randomization. For patients ventilated 28 days or longer and for subjects who die, VFD is 0.
Measure: Ventilator-free days Time: 28 daysTo study signals of efficacy and safety of a currently available dosage form (IM) of EG-HPCP-03a in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.
Description: Patients will be assessed for COVID-19 Ordinal Scale for Clinical Improvement scores and respiratory status throughout the study
Measure: The proportion of patients alive and without respiratory failure Time: First dose date to 28 days treatment dosing periodLow-dose glucocorticoid treatment is the only intervention shown to significantly reduce mortality in cases of COVID-19 pneumonia requiring oxygen supplementation or ventilatory support. In particular, a large UK randomized controlled trial (RECOVERY trial) demonstrated the efficacy of dexamethasone at a dosage of 6mg/day for 10 days in reducing mortality compared to usual therapy, with a greater impact on patients requiring mechanical ventilation (36% reduction) or oxygen therapy (18% reduction) than on those who did not need respiratory support (doi: 10.1056/NEJMoa2021436). However, there is still paucity of information guiding glucocorticoid administration in severe pneumonia/ARDS and no evidence of the superiority of a steroid drug -nor of a therapeutic scheme- compared to the others, which led to a great heterogeneity of treatment protocols and misinterpretation of available findings. In a recent longitudinal observational study conducted in Italian respiratory high-dependency units, a protocol with prolonged low-dose methylprednisolone demonstrated a 71% reduction in mortality and the achievement of other secondary endpoints such as an increase in ventilation-free days by study day 28 in a subgroup of patients with severe pneumonia and high levels of systemic inflammation (doi: 10.1093/ofid/ofaa421). The treatment was well tolerated and did not affect viral shedding from the airways. In light of these data, the present study aims to compare the efficacy of a methylprednisolone protocol and that of a dexamethasone protocol based on previous evidence in increasing survival by day 28, as well as in reducing the need and duration for mechanical ventilation, among hospitalized patients requiring noninvasive respiratory support (oxygen supplementation and/or noninvasive ventilation).
Description: Survival proportion at 28 days in both arms
Measure: Survival Time: 28 daysDescription: Number of days free from mechanical ventilation (either noninvasive or invasive) by study day 28 in both arms
Measure: Reduction in the need for mechanical ventilation Time: 28 daysDescription: Number of days of hospitalization for patients discharged alive in both arms
Measure: Length of hospitalization Time: From date of randomization until the date of hospital discharge, assessed up to 60 daysDescription: Proportion of patients requiring tracheostomy in both arms
Measure: Need for tracheostomy Time: Day 28Description: C-reactive protein level (mg/L) at study day 3, 7 and 14 in both arms
Measure: Reduction in systemic inflammation markers Time: Day 3, 7 and 14Description: PaO2/FiO2 ratio (mmHg) at study day 3, 7 and 14 in both arms
Measure: Amelioration of oxygenation Time: Day 3, 7 and 14Description: WHO clinical progression scale at study day 3, 7 and 14 in both arms
Measure: Disease progression Time: Day 3, 7 and 14ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir. Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests, oropharyngeal (OP) swabs, plasma (Day 29), and serum for secondary research as well as clinical outcome data. However, if infection control or other restrictions limit the ability of the subject to return to the clinic, these visits may be conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. The primary objective is to evaluate the clinical efficacy of baricitinib + remdesivir versus dexamethasone + remdesivir as assessed by the mechanical ventilation free survival by Day 29.
Description: Reported as international normalized ratio (INR)
Measure: Change from baseline in prothrombin time (PT) Time: Day 1 through Day 29Description: Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening.
Measure: Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs) Time: Day 1 through Day 29Description: An SAE is defined as an AE or suspected adverse reaction is considered serious if, in the view of either the investigator or the sponsor, it results in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
Measure: Cumulative incidence of serious adverse events (SAEs) Time: Day 1 through Day 29Description: Desirability of Outcome Ranking (DOOR) based on ordinal scale: 1) Recovered (category 1, 2 or 3 on ordinal scale); 2) Improved (> / = 1 category improvement of ordinal scale compared with baseline) & no serious adverse event (SAE); 3) Improved (> / = 1 category improvement of the ordinal scale compared with baseline) & SAE (related or unrelated); 4) No change in ordinal scale from baseline & no SAE; 5) No change in ordinal scale from baseline & SAE (related or unrelated); 6) Worsening (> / = 1 category worse in ordinal scale from baseline); 7) Death.
Measure: Desirability of Outcome Ranking (DOOR) Time: Day 15 through Day 29Description: Measured in days.
Measure: Duration of hospitalization Time: Day 1 through Day 29Description: For any reason.
Measure: Incidence of discontinuation or temporary suspension of study product administration Time: Day 1 through Day 10Description: Date of death (if applicable).
Measure: Subject 14-day mortality Time: Day 1 through Day 15Description: Date of death (if applicable).
Measure: Subject 28-day mortality Time: Day 1 through Day 29Description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.
Measure: Subject clinical status Time: Days 3, 5, 8, 11, 15, 22, and 29Description: The ordinal scale categories are defined as: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.
Measure: The proportion of subjects meeting criteria for one of the 8 ordinal scale categories Time: Day 15Description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.
Measure: Time to an improvement of one category from baseline using an ordinal scale Time: Day 1 through Day 29Description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.
Measure: Time to an improvement of two categories from baseline using an ordinal scale Time: Day 1 through Day 29Description: Day of recovery is defined as the first day on which the subject satisfies one of the following three ordinal scale categories: 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.
Measure: Time to recovery Time: Day 1 through Day 29Prospective, multi-centre, randomized (1:1), parallel group, open-label, study comparing superiority of dexamethasone 20 mg vs. 6 mg. This is an open label study, in which all the participants involved, e.g. health-care persons and patients in the study, will learn about the intervention. Blinded preplanned statistical analysis will be performed. REMED is a pragmatic, multi-centre trial conducted in intensive care units (ICUs) of university academic hospitals in Czech Republic.
Description: VFDs were defined according to recent recommendation (Yehya et al., 2019): Day 0 (day of randomization) Time frame (28 d) Successful extubation (extubation > 48 h without reintubation in a 28-d survivor) Interval reintubations (count from last successful extubation) Death before 28 d (VFD = 0 to penalize nonsurvival, regardless of intubation status) Death after 28 d (censor after 28 d; use 28-d ventilation and survival status for calculating VFDs)
Measure: Number of ventilator-free days (VFDs) at 28 days after randomization Time: 28 daysDescription: WHO clinical progression scale (range, 0-10, where 0 = no illness, 1-9 = increasing level of care, and 10 = death) (WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection, 2020) assessed at day 14
Measure: WHO clinical progression scale at day 14 Time: 14 daysDescription: need for insulin administration until day 28 or hospital discharge
Measure: Adverse events related to corticosteroids Time: 28 daysDescription: new infection until day 28 or hospital discharge
Measure: Adverse events related to corticosteroids Time: 28 daysDescription: Death from any cause at 180 and 360 days
Measure: Long-term outcome regarding mortality Time: 180 and 360 daysDescription: Functional independence assessed by Barthel Index (BI) assessed at 180 and 360 days
Measure: Long-term outcome regarding functional independence Time: 180 and 360 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports